Qualigen Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.9345
- Today's High:
- $1
- Open Price:
- $1
- 52W Low:
- $0.83
- 52W High:
- $3.535
- Prev. Close:
- $0.97
- Volume:
- 38342
Company Statistics
- Market Cap.:
- $5.10 million
- Book Value:
- 0.403
- Revenue TTM:
- $6.07 million
- Operating Margin TTM:
- -264.4%
- Gross Profit TTM:
- $680801
- Profit Margin:
- -288.66%
- Return on Assets TTM:
- -50.75%
- Return on Equity TTM:
- -185.53%
Company Profile
Qualigen Therapeutics Inc had its IPO on 2015-06-24 under the ticker symbol QLGN.
The company operates in the Healthcare sector and Biotechnology industry. Qualigen Therapeutics Inc has a staff strength of 31 employees.
Stock update
Shares of Qualigen Therapeutics Inc opened at $1 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.93 - $1, and closed at $0.95.
This is a -2.06% slip from the previous day's closing price.
A total volume of 38,342 shares were traded at the close of the day’s session.
In the last one week, shares of Qualigen Therapeutics Inc have slipped by -5.94%.
Qualigen Therapeutics Inc's Key Ratios
Qualigen Therapeutics Inc has a market cap of $5.10 million, indicating a price to book ratio of 0.4921 and a price to sales ratio of 1.1783.
In the last 12-months Qualigen Therapeutics Inc’s revenue was $6.07 million with a gross profit of $680801 and an EBITDA of $-15827476. The EBITDA ratio measures Qualigen Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Qualigen Therapeutics Inc’s operating margin was -264.4% while its return on assets stood at -50.75% with a return of equity of -185.53%.
In Q2, Qualigen Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 13.7%.
Qualigen Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-4.16 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Qualigen Therapeutics Inc’s profitability.
Qualigen Therapeutics Inc stock is trading at a EV to sales ratio of 0.3678 and a EV to EBITDA ratio of -0.1047. Its price to sales ratio in the trailing 12-months stood at 1.1783.
Qualigen Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $13.15 million
- Total Liabilities
- $8.49 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $48409
- Dividend Payout Ratio
- 0%
Qualigen Therapeutics Inc ended 2024 with $13.15 million in total assets and $0 in total liabilities. Its intangible assets were valued at $13.15 million while shareholder equity stood at $2.03 million.
Qualigen Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $8.49 million in other current liabilities, 42952.00 in common stock, $-110695598.00 in retained earnings and $625602.00 in goodwill. Its cash balance stood at $1.34 million and cash and short-term investments were $1.34 million. The company’s total short-term debt was $2,034,729 while long-term debt stood at $0.
Qualigen Therapeutics Inc’s total current assets stands at $4.86 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $679380.00 compared to accounts payable of $1.76 million and inventory worth $1.56 million.
In 2024, Qualigen Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $48409.
Comparatively, Qualigen Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.95
- 52-Week High
- $3.535
- 52-Week Low
- $0.83
- Analyst Target Price
- $40
Qualigen Therapeutics Inc stock is currently trading at $0.95 per share. It touched a 52-week high of $3.535 and a 52-week low of $3.535. Analysts tracking the stock have a 12-month average target price of $40.
Its 50-day moving average was $1.04 and 200-day moving average was $1.12 The short ratio stood at 0.47 indicating a short percent outstanding of 0%.
Around 1155.5% of the company’s stock are held by insiders while 216.8% are held by institutions.
Frequently Asked Questions About Qualigen Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.